Last updated on February 2018

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Brief description of study

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

Clinical Study Identifier: NCT02913456

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: MO39146 ...

Ospedale San Luca; Oncologia
Lucca, Italy
  Connect »